>> Continued From the Previous Page <<
But your body has a secret weapon: an enzyme called fructosamine 3-kinase, or FN3K for short. It’s like a microscopic janitor, sweeping up stray sugar attachments. Until now, scientists thought its role was just routine maintenance. But a new discovery flips that idea on its head.
A top research team led by Professor Leemor Joshua-Tor has uncovered something remarkable. In some cases, glycation—the very process long considered harmful—may actually slow down cancer.
“The tumor needs a lot of sugar to grow,” she explains. “Because of that, the sugar gets attached spontaneously onto this protein and dampens it. It’s like stuffing something in its mouth. The tumor can’t proliferate and grow.”
That’s right. Cancer cells get so sugar-hungry, they choke on it. And that simple overload may offer a new way to stop tumors from spreading.
Even though FN3K was discovered over two decades ago, no one knew how it was structured—until now. Without a blueprint, targeting it with drugs was like trying to build a rocket ship without schematics.
But Joshua-Tor and fellow researcher Ankur Garg used cutting-edge imaging to map FN3K’s structure. Now, for the first time ever, scientists can see exactly how this enzyme works on a molecular level.
“Kinases are common in our cells,” Joshua-Tor says. “So, in order to target only FN3K, and not the other kinases we need, we have to know exactly what it looks like. This gives us a precise model.”
Here’s where it gets even more interesting. The FN3K enzyme contains a crucial piece: tryptophan. You’ve probably heard of it—it’s the stuff in turkey that makes you sleepy after Thanksgiving dinner.
But inside FN3K, tryptophan has a much more serious job. When scientists removed it, the enzyme failed completely. When they replaced it with something else, the enzyme got even stronger.
“Controlling one tiny amino acid can control the whole enzyme,” Garg explains. “This is important for designing specific drugs to target only FN3K.”
This small molecular tweak could lead to huge medical breakthroughs. By manipulating FN3K, scientists may be able to either boost or block its effects—depending on what’s needed to stop cancer in its tracks.
This isn’t just academic research collecting dust in a journal. Teams at Memorial Sloan Kettering Cancer Center are already on the hunt for drugs that could interact with FN3K and either strengthen the body’s defenses—or cut off sugar from cancer cells.
“It’s really remarkable when you think about it,” Joshua-Tor adds. “These enzymes are so fine-tuned that everything has to be in the right state at the right time. It would be great if we could exploit that with an initial drug or molecule and go forward from there.”
This discovery marks a shift in how doctors could treat cancer in the future—not with toxic chemicals that destroy healthy cells, but by leveraging the body’s own defense systems. Starving cancer by turning its own sugar addiction against it may be the next big leap in oncology.
For years, FN3K remained a mystery. Now, with its structure unlocked and its potential unveiled, researchers may finally have a new key in the fight against a disease that has devastated too many lives for far too long.
America’s war on cancer has a new weapon—and it’s one our bodies have possessed all along. With bold minds and relentless research, hope is no longer a fantasy. It’s beginning to look like a plan.
